KLRK1 and neoplasm: Compared with NKG2D/CD3ζ-CAR-T, NKG2D/DAP12-CAR-T secreted less interferon (IFN)-γ, TNF-α, and IL-2 during tumor cell lysis and mitigated the risk of CRS (34).